Omalizumab
Article Abstract:
Allergic asthmas and the hay fever are becoming more common and affecting approximately 10 to 40 percent of the people living in developed countries. Omalizumab was granted approval in June 2003 to be used for treating patients with moderate to severe asthma and for those patients who do not respond very well to the treatment of inhaled corticosteroids.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Japan, Product introduction, New Products/Services, Pharmaceutical industry, Drug therapy, Asthma, Sankyo Company Ltd., Omalizumab (Medication)
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Marimastat fails again
Article Abstract:
Share prices of British Biotech fell 16% after its metalloproteinase inhibitor drug, Marimastat, failed its first clinical trial.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
United Kingdom, Product information, Pharmaceutical Preparation Manufacturing, Enzyme Inhibitors, Brief Article, British Biotech PLC
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Similar abstracts:
- Abstracts: Tuesday Morning, Inc. Mac Frugal's Bargains Inc. Costco Wholesale Corporation
- Abstracts: Similarity judgments in strategy formulation: role, process and implications. Dynamic interaction between strategy and technology
- Abstracts: Media savvy. Profit and loss rapport
- Abstracts: Sliding dollar. Rooms for rent. Call to widen availability of hedge funds
- Abstracts: CLERP 9 Bill on the table. What it's all about
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.